

Onglyza - (2.5 mg and 5 mg; Tablet, Oral)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | SAXAGLIPTIN HYDROCHLORIDE | Innovator | Astrazeneca |
| Dosage | 2.5 mg and 5 mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.